Target analysis and screening strategy planning
We propose the optimal research strategy according to your drug discovery target and development concept.
Based on the target molecule's expression pattern, mechanism of action, epitope requirements, and non-clinical development plan, we clarify the characteristics of the antibody to be acquired.
Support details
- Targeted biology analysis
- Epitope Strategy Planning
- Agonist/Antagonist Strategy Design
- Design of an internalization-inducing antibody strategy
- Cross-reactive antibody acquisition strategy
- Modality adaptability study
VHH antibody acquisition
Utilizing EME's proprietary cDNA Display technology, we obtain target antibodies from a diverse range of VHH libraries.
In addition to screening using purified antigens, we also offer antibody acquisition against natural structural targets using cell panning.
Examples of targets that can be targeted
- cell surface receptors
- Receptor tyrosine kinase (RTK)
- cytokine receptors
- Cancer-related antigens
- GPCR
- Ion channels
- Other membrane proteins
- intracellular target
Examples of obtainable antibodies
- high affinity antibody
- Cross-reactive antibodies
- Epitope-selective antibodies
- Internalization-inducing antibody
- functional antibody
Development aptitude assessment
We evaluate the potential for development as a drug candidate.
We conduct physical property evaluations that consider not only binding activity but also manufacturing and formulation, supporting the selection of candidates with low development risk.
Evaluation item
- binding affinity
- Thermal stability
- cohesiveness
- soluble
- Expression
- Epitope Analysis
- Competitive evaluation
Support for selecting development candidates
We can also provide you with a physical sample of the acquired VHH antibody for functional evaluation. This allows you to evaluate not only its binding activity to the target, but also its biological function, enabling you to select potential development candidates.
Customer Reviews
- Agonist Activity Evaluation
- Antagonist activity evaluation
- Signal transduction analysis
- Internalization evaluation
- Cell proliferation evaluation
- Reporter assay
- Flow cytometry analysis
Lead Optimization
We optimize the acquired candidate antibodies into molecules suitable for drug discovery and development.
We propose various molecular design options depending on the target modality and mechanism of action.
Optimization Menu
- Improved affinity
- Improved specificity
- Diversification
- double singularization
- Fc fusion
- Half-life extension design
- pH-dependent binding control
- Agonist Activity Optimization
Next-generation modality development
Leveraging the small size, high stability, and high design flexibility of VHH, we aim to create new therapeutic concepts. We will utilize the acquired VHH antibodies to support the development of integration with various next-generation modalities, including ADCs, radiopharmaceuticals, CAR-T/CAR-NK cell therapy, LNP active targeting, and multispecific antibodies.
Supported Modalities
- Antibody-Drug Conjugates (ADC)
- Radiopharmaceuticals
- CAR-T/CAR-NK cell therapy
- LNP Active Targeting
- Multispecific antibodies
- Cell and gene therapy related technologies